Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has partnership with Berry Genomics. The company was founded in 2011 and is headquartered in Menlo Park, California.

Date	Fund	Action	%
2023/05/02	ARKG	Buy	0.0111
2023/05/01	ARKG	Buy	0.0018
2023/04/28	ARKG	Buy	0.0099
2023/03/01	ARKG	Buy	0.0091
2023/02/28	ARKG	Buy	0.0002
2023/02/27	ARKG	Buy	0.0022
2023/02/24	ARKG	Buy	0.0082
2023/01/05	ARKG	Buy	0.0184
2023/01/04	ARKG	Buy	0.0004
2023/01/03	ARKG	Buy	0.0053
2022/11/04	ARKG	Buy	0.0307
2022/11/03	ARKG	Buy	0.0109
2022/08/09	ARKG	Buy	0.0147
2022/08/08	ARKG	Buy	0.0022
2022/08/05	ARKG	Buy	0.014
2022/08/01	ARKG	Buy	0.0028
2022/07/29	ARKG	Buy	0.0061
2022/07/28	ARKG	Buy	0.0136
2022/04/26	ARKG	Buy	0.0111
2022/04/25	ARKG	Buy	0.0027
2022/04/20	ARKG	Buy	0.0082
2022/04/19	ARKG	Buy	0.0042
2022/04/18	ARKG	Buy	0.003
2022/04/13	ARKG	Buy	0.0015
2022/04/12	ARKG	Buy	0.0266
2022/04/11	ARKG	Buy	0.0141
2022/02/28	ARKG	Buy	0.0041
2022/02/10	ARKG	Buy	0.0028
2022/02/08	ARKG	Buy	0.0001
2022/02/07	ARKG	Buy	0.0101